A phase Ib clinical evaluation of Venetoclax in combination with chemotherapy in older patients with Acute Myeloid Leukemia
Latest Information Update: 22 Jan 2024
At a glance
- Drugs Venetoclax (Primary) ; Cytarabine; Idarubicin; Posaconazole
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms CAVEAT
- 12 Dec 2023 Results of post-hoc analysis assessing efficacy of venetoclax in combination with chemotherapy in NPM1(mut) AML, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Updated Results (Data cut-off; 31 Mar 2022 ,n=69)assessing High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly patients with Acute Myeloid Leukemia published at the 64th American Society of Hematology Annual Meeting and Exposition
- 20 Jul 2020 Status changed from recruiting to completed, according to results published in the Journal of Clinical Oncology.